THE MBL77 DIARIES

Unfit patients even have the choice of venetoclax in addition obinutuzumab (VO) as frontline therapy. This relies on a stage III demo that in comparison VO with ClbO in elderly/unfit patients.113 VO was outstanding in terms of response price and development-cost-free survival, and had a equivalent security profile. On this demo VO was administered